Skip to main content
Premium Trial:

Request an Annual Quote

Hologic to Complete Third Wave Purchase Today

NEW YORK (GenomeWeb News) – Hologic said that it would complete its $580 million acquisition of Third Wave Technologies after the close of business today.
 
The Bedford, Mass.-based medical imaging and diagnostics firm said that as of midnight last night, Third Wave shareholders had tendered 47,968,050 shares of the firm, representing 95.8 percent of Third Wave’s outstanding stock. Hologic paid $11.25 per share for Third Wave’s stock, which will cease trading on the Nasdaq after today.
 
The acquisition, which was announced in early June, will provide Hologic with complementary products targeted to the women’s health and diagnostics market. Hologic sells the ThinPrep pap test, while Madison, Wis.-based Third Wave recently filed for US Food and Drug Administration clearance for two molecular diagnostic tests for human papillomavirus.
 
 

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.